Search for: "Kirin v. Kirin"
Results 1 - 20
of 83
Sorted by Relevance
|
Sort by Date
2 May 2017, 6:45 pm
Here's some fun with offers from Kirin Produce Co. v. [read post]
19 Nov 2021, 7:47 am
Conwood v. [read post]
12 Aug 2014, 9:55 pm
By Ralph Cox* and Simon Spink** -- Overview For the best part of 10 years, since the judgment of Lord Hoffmann in Kirin-Amgen v Hoescht Marion Roussel[1], it has been widely assumed that there is no file wrapper estoppel in the UK and no doctrine of equivalents either. [read post]
9 Apr 2007, 11:40 am
We used to have a Farrell's Ice Cream Parlour in nearby Springfield Mall when I was a kid growing up in Virginia. [read post]
12 Jul 2018, 6:19 am
The Warner-Lambert v Actavis case concerning the drug pregabalin was heard by the Supreme Court in mid-February 2018 and considered, among other things, plausibility, infringement of second medical use patents and abuse of process. [read post]
29 Jun 2018, 3:08 am
Brian Corderyby Craig Lumb After a decade-long hiatus, so-called Arrow declarations are now firmly back in fashion after the Court of Appeal’s judgment last year in Fujifilm Kyowa Kirin Biologics Co, Ltd v Abbvie Biotechnology Ltd & Anor [2017] EWCA Civ 1. [read post]
13 Jan 2017, 9:24 am
The Court of Appeal decided yesterday that the High Court can, as a point of principle, properly grant declarations that a product lacked novelty or an inventive step at a particular date, see Fujifim Kyowa Kirin Biologics Co., Ltd v AbbVie Biotechnology Limited and Others [2017] EWCA Civ 1. [read post]
10 May 2018, 11:12 pm
Remington [1990] FSR 181; and Kirin-Amgen v. [read post]
3 Mar 2018, 4:02 am
It's now 13 years since Lord Hoffmann told us definitively how to interpret patents claims, in his opinion in Kirin Amgen v Hoechst Marion Roussel [2005] 1 All ER 667. [read post]
10 Dec 2014, 12:31 am
What Birss J has now done is to say "The EPO approach to the interpretation is a novelty rule, not a construction rule, and Kirin-Amgen shows that to be so". [read post]
1 Nov 2019, 6:02 am
In Neo v Anan Kasei([2019]EWCA Civ 1646) the Court of Appeal again considered the thorny issue of insufficiency, both the Kirin-Amgenand the Biogen kind. [read post]
7 Sep 2010, 6:10 pm
Highlights this week included: CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector) Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor) Aranesp (Darbepoetin) – EU: ECJ says ‘no’ to Kirin Amgen,… [read post]
23 Jun 2011, 2:03 am
Currently, an unsuccessful opponent is not estopped from bringing revocation proceedings, largely because of the difference in onus applying at the opposition versus revocation stage: Genetics Institute v Kirin-Amgen at [17] and note Clinique at [13] (trade mark). [read post]
15 May 2014, 11:40 am
Kirin-Amgen might perhaps be regarded as an example of this. [read post]
13 May 2015, 7:58 am
Oliva et al. v. [read post]
28 Mar 2018, 8:14 am
VEGF-Trap is therefore one of those improvements which Lord Hoffmann had in mind in Kirin-Amgen [2004] UKHL 46, [2005] RPC 9 at [117]. [read post]
20 Aug 2012, 4:31 am
., AND KYOWA HAKKO KIRIN CO. [read post]
12 Jul 2017, 1:34 pm
It is here - the Supreme Court's decision in Eli Lilly v Actavis UK [2017] UKSC 48. [read post]
12 Jul 2017, 7:59 am
Eli Lilly v Actavis UK [2017] UKSC 48This is an important case about whether drugs manufactured by Actavis infringe a European patent of Lilly. [read post]
31 Jul 2009, 1:50 pm
W L Gore & Associates GmbH v. [read post]
